An ex­o­dus of top Gilead ex­ecs con­tin­ues as new­ly named CMO An­drew Cheng heads for the ex­it

The ex­o­dus of top ex­ecs out of a high-per­form­ing Gilead is con­tin­u­ing Tues­day evening.

The biotech, which has been the most pro­duc­tive drug de­vel­op­er over the past 5 years, not­ed Tues­day night that Chief Med­ical Of­fi­cer An­drew Cheng is leav­ing the com­pa­ny “to pur­sue an­oth­er op­por­tu­ni­ty.”

As of now, we don’t know what that oth­er op­por­tu­ni­ty is, but Gilead $GILD has re­cent­ly seen the de­par­ture of chief R&D ex­ec Nor­bert Bischof­berg­er (to a start­up) as well as the an­nounced ex­its of CEO John Mil­li­gan and long­time com­pa­ny ex­ec John Mar­tin, ex­ec­u­tive chair­man.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.